ΓΡΗΓΟΡΗΣ ΣΑΡΑΝΤΗΣ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΚΑΛΛΥΝΤΙΚΩΝ, ΕΝΔΥΜΑΤΩΝ, ΟΙΚΙΑΚΩΝ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΕΙΔΩΝ financials
ΓΡΗΓΟΡΗΣ ΣΑΡΑΝΤΗΣ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΚΑΛΛΥΝΤΙΚΩΝ, ΕΝΔΥΜΑΤΩΝ, ΟΙΚΙΑΚΩΝ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΕΙΔΩΝ
Country: GR Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
21380078FJXYHFE8KP46 Financial statements
(EUR, as reported — unscaled; 105 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €600.1M | €482.2M |
| Cost of sales | €373.8M | €299.9M |
| Gross profit | €226.2M | €182.3M |
| Other income | €1.2M | €1.0M |
| Distribution costs | €133.4M | €112.2M |
| Administrative expenses | €32.3M | €24.1M |
| Operating profit (EBIT) | €61.0M | €47.1M |
| Net finance income / (cost) | -€4.3M | €1.9M |
| Profit before tax | €56.7M | €48.6M |
| Income tax expense | €11.3M | €8.8M |
| Profit for the year | €46.1M | €39.0M |
| — attributable to owners | €46.0M | €39.3M |
| — attributable to NCI | €31.2K | -€293.8K |
| Total comprehensive income | €51.2M | €50.1M |
| Per share | ||
| Basic EPS | €0.71 | €0.59 |
| Diluted EPS | €0.71 | €0.59 |
| Cash flow statement | ||
| Net cash from operating activities | €61.9M | €59.3M |
| Net cash from investing activities | -€43.6M | -€6.9M |
| Net cash from financing activities | -€81.4M | -€5.7M |
| Dividends paid | €14.7M | €9.8M |
| Proceeds from borrowings | €24.3M | €55.8M |
| Repayments of borrowings | €69.0M | €34.2M |
| Lease liability payments | €6.8M | €5.0M |
| Net change in cash | -€63.1M | €46.7M |
| Balance sheet | ||
| Total assets | €600.3M | €553.5M |
| Non-current assets | €288.6M | €234.9M |
| Property, plant & equipment | €130.7M | €104.4M |
| Right-of-use assets | €20.5M | €18.0M |
| Intangible assets & goodwill | €14.3M | €7.8M |
| Current assets | €311.7M | €318.7M |
| Inventories | €111.1M | €95.4M |
| Cash & equivalents | €47.4M | €111.0M |
| Total equity | €374.9M | €353.6M |
| — attributable to owners | €374.6M | €353.6M |
| Non-controlling interests | €280.5K | €0 |
| Non-current liabilities | €96.7M | €90.9M |
| Long-term borrowings | €49.6M | €56.1M |
| Lease liabilities (non-current) | €17.4M | €13.6M |
| Current liabilities | €128.6M | €109.0M |
| Short-term borrowings | €9.9M | €14.2M |
| Lease liabilities (current) | €6.9M | €5.1M |
| Trade & other payables | €84.9M | €70.0M |
| Deferred tax liabilities | €16.3M | €9.1M |
| Derived metrics | ||
| Operating margin | 10.2% | 9.8% |
| Net margin | 7.7% | 8.1% |
| Return on equity | 12.3% | 11.0% |
| Cash conversion ratio | 1.34× | 1.52× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€4.7M | €11.0M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€8.7M | -€980.2K |
| Adjustments For Depreciation and Amortisation Expense | €20.6M | €14.5M |
| Adjustments For Fair Value Gains Losses | -€47.1K | €284.8K |
| Adjustments For Finance Costs | €6.0M | €4.6M |
| Adjustments For Increase Decrease In Trade Account Payable | €8.6M | -€1.1M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€33.5K | -€767.4K |
| Cancellation of Treasury Shares | — | €0 |
| Cash and Cash Equivalents Classified As Part of Disposal Group Held For Sale | -€426.2K | €0 |
| Cash Flows From Used In Decrease Increase In Restricted Cash and Cash Equivalents | €595.0K | -€595.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €28.0M | €3.2M |
| Comprehensive Income Attributable To Noncontrolling Interests | €20.7K | -€527.1K |
| Comprehensive Income Attributable To Owners of Parent | €51.2M | €50.6M |
| Current Financial Assets At Fair Value Through Profit Or Loss | €3.6M | €3.0M |
| Current Tax Liabilities | €5.4M | €3.1M |
| Deferred Tax Assets | €682.0K | €706.4K |
| Deferred Tax Expense Income | -€604.4K | €877.9K |
| Dividends Received Classified As Investing Activities | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€144.6K | €3.6M |
| Equity and Liabilities | €600.3M | €553.5M |
| Gains Losses On Exchange Differences On Translation Net of Tax | €1.0M | €6.7M |
| Income Tax Relating To Changes In Revaluation Surplus of Other Comprehensive Income | €1.1M | €1.3M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €21.7K | -€28.8K |
| Income Taxes Paid Refund Classified As Operating Activities | €8.6M | €6.7M |
| Increase Decrease Through Acquisition of Subsidiary | €259.7K | -€5.0M |
| Increase Decrease Through Appropriation of Retained Earnings | — | -€488.1K |
| Increase Decrease Through Sharebased Payment Transactions | €659.1K | €256.2K |
| Increase Decrease Through Transfer To Statutory Reserve | €0 | €0 |
| Intangible Assets Other Than Goodwill | €94.4M | €57.3M |
| Interest Paid Classified As Operating Activities | €6.5M | €4.1M |
| Interest Received Classified As Investing Activities | €1.3M | €3.1M |
| Investment Property | €8.2M | €6.8M |
| Investments In Subsidiaries Joint Ventures and Associates | €0 | €0 |
| Issue of Equity | €37 | — |
| Issued Capital | €52.1M | €52.1M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €323.6K | €0 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €1.1M | €0 |
| Noncurrent Provisions For Employee Benefits | €2.4M | €1.6M |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | -€2.4M | -€6.2M |
| Other Comprehensive Income | €5.1M | €11.1M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €88.9K | -€139.2K |
| Other Comprehensive Income Before Tax Gains Losses On Revaluation | €5.1M | €5.7M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €67.2K | -€110.4K |
| Other Comprehensive Income Net of Tax Gains Losses On Revaluation | €4.0M | €4.5M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €1.0M | €6.7M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €4.1M | €4.4M |
| Other Current Liabilities | €21.3M | €16.4M |
| Other Current Receivables | €33.6M | €8.0M |
| Other Expense By Nature | €873.6K | €0 |
| Other Noncurrent Assets | €19.7M | €40.0M |
| Other Noncurrent Liabilities | €11.0M | €10.6M |
| Other Reserves | €23.2M | €32.4M |
| Proceeds From Government Grants Classified As Investing Activities | €50.9K | €473.4K |
| Purchase of Treasury Shares | €15.8M | €12.0M |
| Reserve of Exchange Differences On Translation | -€6.5M | -€7.5M |
| Retained Earnings | €265.1M | €236.0M |
| Share Premium | €40.7M | €40.7M |
| Trade Receivables | €114.9M | €101.3M |
Methodology
Every line item above is a fact tagged in ΓΡΗΓΟΡΗΣ ΣΑΡΑΝΤΗΣ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΚΑΛΛΥΝΤΙΚΩΝ, ΕΝΔΥΜΑΤΩΝ, ΟΙΚΙΑΚΩΝ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΕΙΔΩΝ's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.